Gilead Sciences
GILD
1,544 hedge funds and large institutions have $68.5B invested in Gilead Sciences in 2021 Q2 according to their latest regulatory filings, with 110 funds opening new positions, 647 increasing their positions, 570 reducing their positions, and 117 closing their positions.
39% more funds holding in top 10
Funds holding in top 10: 23 → 32 (+9)
14% more repeat investments, than reductions
Existing positions increased: 647 | Existing positions reduced: 570
8% more capital invested
Capital invested by funds: $63.4B → $68.5B (+$5.07B)
1.13% more ownership
Funds ownership: 78.24% → 79.38% (+1.1%)
4% more call options, than puts
Call options by funds: $1.59B | Put options by funds: $1.53B
6% less first-time investments, than exits
New positions opened: 110 | Existing positions closed: 117
1% less funds holding
Funds holding: 1,567 → 1,544 (-23)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$701M |
| 2 |
Goldman Sachs
New York
|
+$377M |
| 3 |
Parnassus Investments
San Francisco,
California
|
+$325M |
| 4 |
Morgan Stanley
New York
|
+$114M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$95.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$396M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$332M |
| 3 |
Holocene Advisors
New York
|
-$132M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$117M |
| 5 |
Renaissance Technologies
New York
|
-$101M |
GILD Hedge Fund Activity: Q2 2021 in Review
1,544 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2021, worth a combined $68.5B — up 8% from $63.4B a quarter earlier.
Sellers outnumbered buyers: 117 funds closed out of GILD and 110 opened new positions — a net loss of 7 holders — while 570 trimmed existing stakes and 647 added.
The largest buyer was Dodge & Cox, adding an estimated $701M. The largest seller was Capital Research Global Investors, cutting an estimated $396M.
- 1,544 institutional investors held Gilead Sciences (GILD) as of Q2 2021, down from 1,567 in Q1 2021.
- Funds reported $68.5B of Gilead Sciences stock for Q2 2021, up 8% quarter-over-quarter.
- 110 funds opened new Gilead Sciences positions in Q2 2021 and 117 closed out, a net change of -7 holders.
- The largest Gilead Sciences buyer in Q2 2021 was Dodge & Cox, an estimated $701M added.
- The largest Gilead Sciences seller in Q2 2021 was Capital Research Global Investors, an estimated $396M sold.
Based on aggregated 13F filings for Q2 2021.